Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850776 | 0.93 | HTR2B (0.43) | HTR2BGPR35MAOBMAPTTSHR | |
| SCHEMBL12850797 | 0.90 | HTR2B (0.40) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL26121507 | 0.90 | HTR2B (0.40) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL12850779 | 0.90 | HTR2B (0.40) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL21515889 | 0.90 | HTR2B (0.40) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL21515798 | 0.90 | HTR2B (0.40) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL20180857 | 0.90 | HTR2B (0.42) | HTR2BGPR35PTPN11MAOB | |
| SCHEMBL18189564 | 0.90 | MAPT (0.44) | HTR2BGPR35PTPN11MAPTTSHR | |
| SCHEMBL18189563 | 0.90 | MAPT (0.44) | HTR2BGPR35PTPN11MAPTTSHR | |
| SCHEMBL20180893 | 0.87 | HTR2B (0.43) | HTR2BGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | FECH, SLC19A1, SLC40A1 | HTR2B 2007/4885GPR35 1607/4885PTPN11 4644/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | HTR2B 2007/4885GPR35 1607/4885PTPN11 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.